Clinical Trial Update: Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial of Orantinib with transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Orantinib (Orantinib)

Snippet

Sponsor: Taiho Pharmaceutical Co., Ltd. | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2019-08-07